REVIEW & SPECIAL ARTICLE

Hypoxic Pulmonary Vasoconstriction: Relevance to Anesthetic Practice

Pattharaporn Sombood, BNS[1], Supanadee Jainwitayakit, MEd[1], Amornrat Aekta, BNS[1], Ingpisa Sritanapongsa, BNS[1], Phongthara Vichitvejpaisal, MD, PhD[1]

[1] Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Hypoxic pulmonary vasoconstriction (HPV) is a physiological response of the pulmonary vasculature to hypoxia, resulting in vasoconstriction in poorly ventilated areas of the lungs and redirecting blood flow to well-ventilated areas. Understanding the significance of HPV is crucial in the context of anesthesia for perioperative management.

The complex interplay between HPV, oxygen tension, CO_2 levels, and pH is essential for anesthesiologists to tailor ventilation strategies and optimize patient outcomes, particularly in individuals with pre-existing pulmonary hypertension (PH) or acute respiratory distress syndrome. This reflex plays a critical role in maintaining adequate oxygenation during anesthesia by preserving ventilation-perfusion matching and optimizing oxygen delivery to the body through redirection of blood flow to well-ventilated lung regions.

Pharmacological manipulation of HPV using drugs that enhance or inhibit its response can be utilized in specific clinical scenarios, such as in patients with PH or during thoracic surgeries, to optimize hemodynamics and improve patient outcomes.

Future research in anesthesia aims to elucidate the molecular and cellular mechanisms of HPV, investigate genetic and epigenetic factors that influence it, develop novel pharmacological agents, conduct large-scale clinical trials and outcome studies, and foster multidisciplinary collaborations.

Keywords: Anesthesia management; Hypoxic pulmonary vasoconstriction; HPV; Ventilation-perfusion matching

Received 18 September 2024 | Revised 10 January 2025 | Accepted 24 February 2025

J Med Assoc Thai 2025;108(3):250-6

Website: http://www.jmatonline.com

Hypoxic pulmonary vasoconstriction (HPV), also known as the Haldane effect, named after the British physiologist John Scott Haldane, who first described it in 1914[1-3]. HPV is a mechanism that helps regulate blood flow in the lungs and is an important process in maintaining proper ventilation-perfusion (V/Q) matching, which is the balance between the amount of ventilation (airflow, V) and perfusion (blood flow, Q) in different regions of the lungs[2-4].

HPV is mediated by pulmonary vascular smooth muscle cells and vasoactive substances released by endothelial cells. It improves gas exchange, optimizes V/Q matching, and helps maintain pulmonary artery pressure (PAP). Altered HPV can have implications for anesthesia management, especially in patients with lung conditions or during thoracic surgeries[4,5].

Additionally, the respiratory and cardiovascular systems are interdependent and essential for working together to ensure adequate oxygenation and circulation, thereby maintaining the proper functioning of all tissues and organs in the body. The respiratory system facilitates gas exchange and ventilation, while the cardiovascular system circulates blood, delivering oxygen and nutrients, and removing waste products[5].

Hypoxic pulmonary vasoconstriction

Physiology of HPV

The mechanisms of HPV involve complex interactions between various cells, molecules, and physiological processes within the pulmonary vasculature. Smooth muscle cells in the walls of pulmonary arteries, known as pulmonary arterial smooth muscle cells (PASMCs), are the primary effectors of HPV[2-5]. When exposed to hypoxia, PASMCs contract, leading to vasoconstriction and narrowing of the pulmonary arteries. This constriction redirects blood flow to better-ventilated lung regions,

Correspondence to:

Vichitvejpaisal P.

Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand.

Phone: +66-2-4197978, **Fax:** +66-2-4113256

Email: phongthara@gmail.com

How to cite this article:

Sombood P, Jainwitayakit S, Aekta A, Sritanapongsa I, Vichitvejpaisal P. Hypoxic Pulmonary Vasoconstriction: Relevance to Anesthetic Practice. J Med Assoc Thai 2025;108:250-6.

DOI: 10.35755/jmedassocthai.2025.3.250-256-00420

improving V/Q matching and optimizing oxygen exchange[5,6].

Activation of oxygen-sensitive ion channels in PASMCs is a crucial step in initiating HPV. These ion channels respond to hypoxia by increasing intracellular calcium levels, leading to vasoconstriction[5-7]. Additionally, PASMCs experience membrane depolarization due to the inhibition of potassium channels, further contributing to increased calcium levels and subsequent vasoconstriction.

Furthermore, PASMCs release vasoconstrictor mediators, such as endothelin-1, thromboxane A2, and serotonin, in response to alveolar hypoxia. These mediators further contribute to the constriction of the pulmonary arteries, intensifying the overall HPV response.

Endothelial cells, which line the inner surface of blood vessels including the pulmonary arteries, also play a crucial role in regulating HPV. They sense the oxygen levels in the blood and release substances that modulate the tone of the pulmonary arteries. In response to hypoxia, endothelial cells produce nitric oxide (NO), a vasodilator, as well as endothelin-1, a vasoconstrictor. Furthermore, endothelial cells participate in regulating intracellular calcium levels and are involved in inflammation and immune responses[7,8].

Factors influencing HPV

Several factors influence HPV, which plays a crucial role in maintaining V/Q matching. Oxygen tension, CO_2 levels, pH, temperature, and sympathetic nervous system activity all impact HPV[3,4,6,7]. Low oxygen tension in the alveoli is the primary stimulus for HPV, while increased CO_2 and decreased pH can potentiate the response. Additionally, sympathetic activation can enhance HPV[7,8].

Understanding the significance of HPV is particularly important in the context of anesthesia. It helps preserve V/Q matching, maintain PAP, and optimize lung isolation techniques during thoracic surgeries[4-6,9]. However, in patients with pre-existing pulmonary hypertension (PH), HPV can worsen the condition by increasing pulmonary vascular resistance (PVR) and leading to right ventricular dysfunction.

Pharmacological manipulation of HPV can be achieved using drugs such as NO, prostaglandins, and calcium channel blockers. These drugs can either enhance or inhibit HPV[6-9]. However, caution must be exercised when using these agents, as they may have unintended consequences for other physiological processes.

Alveolar hypoxia, which occurs when there are low oxygen levels in the alveoli of the lungs, is a critical factor in HPV. It triggers a vasoconstrictor response in the pulmonary vasculature, redirecting blood flow to well-ventilated lung regions and optimizing oxygen exchange[9,10].

The magnitude of HPV is influenced by the level of alveolar hypoxia, with lower oxygen tensions resulting in stronger vasoconstrictor responses. Other factors such as CO_2 levels, pH, anesthetic drugs, and pulmonary diseases can also modulate the HPV response[7,8,11,12]. An increase in CO_2 levels and a decrease in pH can potentiate HPV, while hyperventilation or respiratory alkalosis can attenuate the response[6,11,13].

The sympathetic nervous system plays a significant role in modulating HPV. Sympathetic activation enhances HPV through the release of neurotransmitters such as norepinephrine[4,8,14]. This activation increases vasoconstriction of the pulmonary vasculature by stimulating alpha-adrenergic receptors on smooth muscle cells and promoting the release of endothelin-1 from endothelial cells.

During anesthesia, other factors can affect HPV[4-6], including increased PVR, age-related changes in the pulmonary vasculature, medications used such as vasodilators or anesthetic agents, changes in acid-base status, alterations in body temperature, inflammatory mediators, and metabolic factors.

Significance of HPV in anesthesia

HPV is a crucial factor to consider in anesthesia practice as it plays a significant role in maintaining proper oxygenation. Anesthesia-related factors can disrupt the balance between V and Q in the lungs, resulting in inadequate oxygenation[2,7,12]. However, HPV comes into play by constricting blood vessels in poorly oxygenated areas, effectively improving oxygenation by redirecting blood flow to well-oxygenated regions of the lungs[15,16].

The changes induced by anesthesia can disturb the normal relationship between lung V and perfusion Q, further affecting gas exchange[7,17,18]. In this scenario, HPV steps in to optimize this match between V and Q, facilitating efficient gas exchange and ensuring adequate arterial oxygenation. By constricting pulmonary blood vessels in response to hypoxia, HPV helps optimize oxygen delivery to the systemic circulation. This mechanism preserves the oxygen-carrying capacity of arterial blood by

reducing the amount of deoxygenated blood entering the systemic circulation.

Anesthesia can lead to V/Q inequalities in the lungs, which impair gas exchange[6,16]. Fortunately, HPV compensates for these inequalities by redistributing blood flow from poorly ventilated or perfused areas to well-ventilated or perfused regions, thereby maintaining overall oxygenation. Anesthesiologists closely monitor oxygen tension, CO_2 levels, and pH during anesthesia, as these parameters influence HPV. By carefully managing these variables, anesthesiologists can optimize HPV and ensure sufficient oxygenation for the patient.

It is important to note that HPV-induced vasoconstriction increases PAP[12,15]. On the other hand, impaired HPV can result in elevated pulmonary blood flow and pressure. In addition, pulmonary circulation is a low-resistance system compared to systemic circulation. When pulmonary blood flow increases due to impaired HPV, there might be an increase in PAP, affecting both the right ventricular afterload and, subsequently, the left ventricular preload. To address this, anesthesiologists closely monitor PAP and adjust anesthesia as needed. This monitoring helps optimize oxygenation and prevents adverse cardiovascular effects that may arise from abnormal PAP.

Preservation of V/Q matching

HPV plays a crucial role in redistributing pulmonary blood flow, V/Q matching, optimizing oxygen delivery, compensating for V/Q inequalities, responding to physiological changes, and influencing PAP. Preservation of V/Q matching is a crucial aspect of HPV in anesthesia. It helps in maintaining a balance between V and Q in the lungs, ensuring efficient gas exchange and adequate oxygenation of arterial blood[5,17]. Anesthesiologists closely monitor V/Q matching to assess gas exchange and oxygenation and intervene if disturbances occurred. Preservation of V/Q matching through HPV involves the redistribution of blood flow, compensation for V/Q inequalities, optimization of oxygenation, and impact on PAP. HPV also affects regional blood flow in the lungs by redirecting blood flow from poorly ventilated or perfused areas to well-ventilated or well-perfused areas, optimizing regional blood flow and preventing shunt physiology[17,18].

Furthermore, the effects of HPV on regional blood flow impact regional V/Q ratios and regional oxygenation, thus ensuring efficient gas exchange and preventing regional hypoxemia. Lastly, V/Q matching is crucial in maintaining oxygenation by allowing for optimal gas exchange, maintenance of arterial oxygenation, prevention of hypoxemia, and improved patient outcomes. Proper V/Q matching becomes even more critical in specific patient populations with preexisting lung diseases or compromised pulmonary function[18,19].

Impact on PAP

HPV plays a crucial role in maintaining PAP, which is the pressure in the pulmonary arteries that carry deoxygenated blood from the heart to the lungs for oxygenation. HPV causes vasoconstriction of the pulmonary arterioles in response to alveolar hypoxia, leading to an increase in PAP[12,15,17]. This increase in pressure helps redirect blood flow to well-ventilated areas of the lungs, optimizing gas exchange and maintaining adequate oxygenation.

Additionally, HPV plays a critical role in redistributing pulmonary blood flow within the lungs. By constricting the pulmonary arterioles in response to hypoxia, HPV helps redirect blood flow to areas of the lungs with better oxygenation[18,20]. This redistribution of blood flow optimizes V/Q matching, improving gas exchange and ensuring adequate oxygenation.

However, patients with pre-existing PH face unique implications related to HPV during anesthesia. PH is characterized by increased PVR and elevated PAP, which can affect the normal HPV response. Anesthesia-induced changes in V, Q, and oxygenation can have a greater impact on these patients, potentially worsening PAP and oxygenation[17,19]. The altered HPV response in PH can compromise the ability to redistribute blood flow and maintain appropriate V/Q matching.

Patients with pre-existing PH may also be at increased risk of hypoxemia, as anesthesia-induced changes in V, Q, and oxygenation can further impair the HPV response[17,20]. Hypoxemia can lead to adverse effects on vital organs and increase the risk of perioperative complications.

Moreover, impaired HPV response during anesthesia can have significant implications for right ventricular function in patients with PH. The increased afterload caused by elevated PAP in PH already compromises the right ventricular function[15,21]. However, there are left and right-side afterloads, which differ in clinical practice. From the context clues, it is apparent that this distinction is important, as an impaired HPV response during anesthesia can further elevate right ventricular

afterload, potentially compromising right ventricular function, reducing cardiac output, and increasing the risk of right ventricular failure[18,21].

Tailored anesthesia management is essential for patients with pre-existing PH. Strategies may include maintaining adequate oxygenation, optimizing V and Q, and closely monitoring hemodynamic parameters. Specialized anesthesia techniques, such as low tidal volume ventilation, positive end-expiratory pressure (PEEP), and judicious fluid management, may be employed to minimize the impact on PAP and optimize patient outcomes. Higher levels of PEEP can potentially compromise venous return, increase right ventricular preload, and exacerbate PH[6,17,20,22]. Collaboration with a multidisciplinary team, including cardiologists and pulmonologists, may be necessary to provide comprehensive care.

Clinical relevance in anesthesia management

HPV holds significant clinical relevance in anesthesia management, impacting various aspects of patient care during surgery. Anesthesia providers must consider HPV's role in maintaining V/Q matching, regulating PAP, and managing patients with respiratory conditions[2,5,17]. The selection of anesthesia techniques and vigilant hemodynamic monitoring are also influenced by HPV. Awareness of HPV's significance enables anesthesia providers to tailor their management strategies and optimize patient outcomes[20,22].

In anesthesia management, considerations span the entire perioperative period, starting with anesthetic induction and maintenance. Airway management, hemodynamic stability, and proper drug selection based on patient-specific factors are crucial[17,19,22]. Monitoring anesthesia depth, managing pain, and fostering effective communication and teamwork are vital components.

During surgery, the impact of HPV on intraoperative ventilation strategies must be recognized. V/Q matching can be influenced by HPV, necessitating careful selection of ventilation strategies and appropriate titration of PEEP and lung recruitment maneuvers. The choice of ventilation mode should consider patient-specific factors and continuous monitoring of oxygenation.

HPV also carries implications for postoperative recovery and management. Respiratory function, oxygenation, and fluid management can be affected. Close monitoring of respiratory parameters, interventions such as incentive spirometry and supplemental oxygen therapy, and balanced fluid management are essential[6,22]. Effective pain management is crucial for optimizing respiratory function. Additionally, managing comorbidities, providing patient education, and ensuring appropriate follow-up contribute to postoperative recovery and management.

Clinical applications

HPV has several clinical applications in various medical settings. It can be used for diagnostic purposes in identifying pulmonary embolism through V/Q scans. In the management of acute respiratory distress syndrome (ARDS), HPV is utilized to optimize ventilation and improve oxygenation. For persistent PH of the newborn (PPHN), therapies targeting HPV, such as inhaled NO, are employed to reduce PAP and improve oxygenation[10,18,23]. Anesthesia management considers the effects of HPV to optimize ventilation and oxygenation during surgery. Therapeutic interventions for PH aim to modulate HPV and improve pulmonary hemodynamics[6,18,19]. HPV can also be evaluated to assess respiratory function in certain disease states, providing information on respiratory adaptation and the efficacy of interventions. Understanding the clinical applications of HPV is valuable for the diagnosis and management of respiratory conditions, anesthesia management, and therapeutic interventions for PH.

Acute respiratory distress syndrome

Ventilation strategies in ARDS patients should consider the implications of HPV. PEEP is commonly used but should be carefully adjusted to balance lung recruitment and optimal HPV for improved V/Q matching[3,4,23]. Tidal volume and plateau pressure should be managed to avoid overdistention and minimize ventilator-induced lung injury, optimizing HPV and V/Q matching[2,5]. Respiratory rate and inspiratory time should be adjusted to prevent dynamic hyperinflation and improve HPV for better V/Q matching and oxygenation[6,22]. Prone positioning can redistribute blood flow, improve HPV, and enhance V/Q matching[17]. Inhaled vasodilators, such as inhaled NO, can selectively reduce HPV and improve pulmonary hemodynamics, but their use should be monitored[9,10]. Extracorporeal support, like extracorporeal membrane oxygenation (ECMO), can optimize HPV and V/Q matching by providing extracorporeal gas exchange. Individualized ventilation strategies tailored to patient characteristics are crucial in managing ARDS effectively[4,23].

Selective lung ventilation during thoracic surgeries

Selective lung ventilation (SLV) is a technique commonly used during thoracic surgeries to isolate and ventilate one lung while allowing the other lung to collapse or deflate[18,22]. This technique provides benefits during thoracic surgeries, including improved surgical access, reduced risk of contamination, protection of the healthy lung, optimization of surgical outcomes, enhanced safety during complex procedures, minimized intraoperative bleeding, and facilitated ventilation strategies[5,6]. It is an important technique used by thoracic surgeons to optimize patient outcomes during thoracic surgeries.

HPV is a physiological response of the lungs to changes in V and Q, and it plays a crucial role in optimizing lung isolation techniques during thoracic surgeries that require one-lung ventilation (OLV)[15,17,20,22,24]. HPV helps redistribute blood flow in the non-ventilated lung during OLV by constricting pulmonary arterioles in poorly ventilated areas, improving V/Q matching and reducing the risk of shunt. It compensates for changes in perfusion, reduces lung injury, maintains oxygenation and ventilation, and facilitates surgical maneuvers[22,25,26].

Pharmacological manipulation of HPV

Pharmacological manipulation of high-pressure ventilation involves the use of medications to modulate the pulmonary vasculature's response to changes in V and Q. These drugs can either enhance or inhibit HPV, depending on the desired therapeutic effect[8,9,14]. Several pharmacological agents are commonly used for manipulating HPV.

Vasodilators, such as inhaled NO, prostacyclin (PGI2), and adenosine, relax the smooth muscle in the pulmonary arterioles, resulting in vasodilation and decreased PVR[4,8,17,19].

This reduces HPV, leads to a V/Q mismatch by redistributing blood flow to poorly ventilated lung areas.

On the other hand, vasoconstrictors like phenylephrine, norepinephrine, and endothelin-1 receptor antagonists constrict the smooth muscle in the pulmonary arterioles, increasing PVR and enhancing HPV[7,8,19]. This redirects blood flow to better-ventilated lung areas, which can contribute to improved V/Q matching.

Certain anesthetic agents also have effects on HPV. Volatile anesthetics like sevoflurane and isoflurane have vasodilatory effects that decrease HPV[20,22,27], while intravenous anesthetic agents like propofol and dexmedetomidine can modulate HPV[22,25], although the mechanisms are not fully understood.

Furthermore, pulmonary surfactant, such as beractant, poractant alfa, and calfactant, can be administered exogenously to improve lung compliance, reduce atelectasis, and potentially enhance HPV[5,28]. This leads to improved V/Q matching.

Conclusion

High-pressure ventilation is a crucial aspect of anesthesia management, as it plays a significant role in optimizing oxygenation and lung function during surgery. HPV improves V/Q matching by redistributing blood flow to well-ventilated areas of the lungs and regulating PAP. It guides intraoperative ventilation strategies, anesthetic agent selection, and techniques to maintain optimal oxygenation and ventilation. Postoperative recovery involves pain management, fluid balance, and ventilation strategies to promote successful lung function and recovery. Pharmacological manipulation of HPV can be employed in specific situations but requires careful consideration and monitoring.

Anesthesia management encompasses considerations for respiratory and cardiovascular systems. Anesthesia's impact on respiratory function necessitates monitoring of oxygen saturation, end-tidal carbon dioxide ($ETCO_2$) levels, and ventilation parameters. Airway management is critical to prevent complications. Anesthesia also affects cardiovascular function, requiring monitoring of blood pressure, heart rate, and cardiac output. Proper selection and titration of anesthetic agents, along with fluid management, ensure cardiovascular stability. Pre-existing medical conditions and patient positioning should be considered for adequate ventilation and circulation. Continuous monitoring, titration, and postoperative recovery strategies are essential, while teamwork ensures safe and effective anesthesia management.

Future research can focus on understanding the mechanisms underlying HPV, including cellular and molecular factors, genetic and epigenetic influences on individual HPV response, and exploring HPV's role in different clinical scenarios. Development of novel pharmacological agents targeting HPV pathways and advancements in non-invasive imaging and molecular biology techniques can contribute to a deeper understanding. Well-designed clinical trials and outcome studies can provide evidence for anesthesia strategies, and multidisciplinary

collaborations can enhance research efforts.

What is already known about this topic?

HPV is a mechanism that helps regulate blood flow in the lungs and is important for maintaining V/Q matching. It is mediated by pulmonary vascular smooth muscle cells and vasoactive substances released by endothelial cells. Factors such as oxygen tension, CO_2 levels, pH, temperature, and sympathetic nervous system activity influence HPV.

Understanding the significance of HPV is important in anesthesia management, as it helps preserve V/Q matching and maintain PAP. Altered HPV can have implications for patients with pre-existing PH.

What does this study add?

This article provides a comprehensive overview of the physiology of HPV, factors influencing HPV, and the significance of HPV in anesthesia management. It emphasizes the importance of HPV in maintaining proper oxygenation, optimizing V/Q matching, and preventing adverse cardiovascular effects.

The article highlights the clinical relevance of HPV in anesthesia management, including its implications for ventilation strategies, lung isolation techniques, and pharmacological manipulation. It discusses the impact of HPV on PAP and its implications for patients with pre-existing PH. It also highlights the preservation of V/Q matching through HPV and its role in maintaining efficient gas exchange and preventing regional hypoxemia.

Clinical applications of HPV in various medical settings, such as the diagnosis and management of respiratory conditions, anesthesia management, and therapeutic interventions for PH, are also discussed. This article emphasizes the need for tailored anesthesia management, close monitoring of hemodynamic parameters, and collaboration with multidisciplinary teams to optimize patient outcomes. Additionally, it concludes by highlighting areas for future research, including further understanding of the mechanisms underlying HPV and the development of novel pharmacological agents targeting HPV pathways.

Conflicts of interest

The authors declare no conflict of interest.

References

1. Sekhar K, Rao SC. John Scott Haldane: The father of oxygen therapy. Indian J Anaesth 2014;58:350-2.
2. Guazzi MD, Berti M, Doria E, Fiorentini C, Galli C, Pepi M, et al. Enhancement of the pulmonary vasoconstriction reaction to alveolar hypoxia in systemic high blood pressure. Clin Sci (Lond) 1989;76:589-94.
3. Jernigan NL, Resta TC, Gonzalez Bosc LV. Altered redox balance in the development of chronic hypoxia-induced pulmonary hypertension. Adv Exp Med Biol 2017;967:83-103.
4. Bickler PE, Feiner JR, Lipnick MS, McKleroy W. "Silent" presentation of hypoxemia and cardiorespiratory compensation in COVID-19. Anesthesiology 2021;134:262-9.
5. Shoni M, Rodriguez G. Intraoperative anesthetic management of the thoracic patient. Thorac Surg Clin 2020;30:279-91.
6. Lumb AB, Slinger P. Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications. Anesthesiology 2015;122:932-46.
7. Sommer N, Strielkov I, Pak O, Weissmann N. Oxygen sensing and signal transduction in hypoxic pulmonary vasoconstriction. Eur Respir J 2016;47:288-303.
8. Dunham-Snary KJ, Wu D, Sykes EA, Thakrar A, Parlow LRG, Mewburn JD, et al. Hypoxic pulmonary vasoconstriction: From molecular mechanisms to medicine. Chest 2017;151:181-92.
9. Iotti GA, Olivei MC, Palo A, Galbusera C, Veronesi R, Braschi A. Acute effects of inhaled nitric oxide in adult respiratory distress syndrome. Eur Respir J 1998;12:1164-71.
10. Marshall BE, Marshall C. The influence of nitric oxide in adult respiratory distress syndrome when Pv(O2) is varied. Anesthesiology 1997;86:1228-30.
11. Loeppky JA, Scotto P, Riedel CE, Roach RC, Chick TW. Effects of acid-base status on acute hypoxic pulmonary vasoconstriction and gas exchange. J Appl Physiol (1985) 1992;72:1787-97.
12. Moudgil R, Michelakis ED, Archer SL. The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation 2006;13:615-32.
13. Archer S, Michelakis E. The mechanism(s) of hypoxic pulmonary vasoconstriction: potassium channels, redox O(2) sensors, and controversies. News Physiol Sci 2002;17:131-7.
14. Kerbaul F, Rondelet B, Motte S, Fesler P, Hubloue I, Ewalenko P, et al. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2004;32:1035-40.
15. Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol (1985) 2005;98:390-403.
16. Waypa GB, Schumacker PT. Hypoxic pulmonary vasoconstriction: redox events in oxygen sensing. J Appl Physiol (1985) 2005;98:404-14.

17. Marquis AD, Jezek F, Pinsky DJ, Beard DA. Hypoxic pulmonary vasoconstriction as a regulator of alveolar-capillary oxygen flux: A computational model of ventilation-perfusion matching. PLoS Comput Biol 2021;17:e1008861.
18. Benzing A, Mols G, Brieschal T, Geiger K. Hypoxic pulmonary vasoconstriction in nonventilated lung areas contributes to differences in hemodynamic and gas exchange responses to inhalation of nitric oxide. Anesthesiology 1997;86:1254-61.
19. Tarry D, Powell M. Hypoxic pulmonary vasoconstriction. BJA Education 2017;17:208-13.
20. Hughes JM. Hypoxic pulmonary vasoconstriction: clinical implications. Eur Respir J 2016;47:31-4.
21. Price LC, Wort SJ, Finney SJ, Marino PS, Brett SJ. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care 2010;14:R169. doi: 10.1186/cc9264.
22. Nagendran J, Stewart K, Hoskinson M, Archer SL. An anesthesiologist's guide to hypoxic pulmonary vasoconstriction: implications for managing single-lung anesthesia and atelectasis. Curr Opin Anaesthesiol 2006;19:34-43.
23. Delong P, Murray JA, Cook CK. Mechanical ventilation in the management of acute respiratory distress syndrome. Semin Dial 2006;19:517-24.
24. Campos JH, Feider A. Hypoxia during one-lung ventilation-a review and update. J Cardiothorac Vasc Anesth 2018;32:2330-8.
25. Rose L. Clinical application of ventilator modes: Ventilatory strategies for lung protection. Aust Crit Care 2010;23:71-80.
26. Valente Barbas CS. Lung recruitment maneuvers in acute respiratory distress syndrome and facilitating resolution. Crit Care Med 2003;31(4 Suppl):S265-71.
27. Bogaard HJ. Hypoxic pulmonary vasoconstriction in COPD-associated pulmonary hypertension: been there, done that? Eur Respir J 2017;50. doi: 10.1183/13993003.01191-2017.
28. Kopp R, Kuhlen R, Max M, Rossaint R. Evidence-based medicine in the therapy of the acute respiratory distress syndrome. Intensive Care Med 2002;28:244-55.